相关实验视频
Updated: Sep 12, 2025

07:44
Localization of the Locus Coeruleus in the Mouse Brain
Published on: March 7, 2019
18.1K
早期的Locus Coeruleus noradrenergic轴突损失导致阿尔茨海默病的嗅觉功能障碍
Carolin Meyer1, Theresa Niedermeier1, Paul L C Feyen1,2
1German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
Nature communications
|August 8, 2025
概括
早期阿尔茨海默氏病 (AD) 涉及由于嗅球 (OB) 中的诺亚上腺素 (NA) 损失导致的嗅觉缺陷. 吞这些NA轴突的微质会导致这种情况,这表明早期AD诊断的嗅觉测试.
科学领域:
- 神经科学是一个神经科学.
- 病理学 病理学 病理学
- 免疫学 免疫学 免疫学
背景情况:
- 阿尔茨海默氏病 (AD) 经常出现早期的非认知症状,如嗅觉缺陷.
- 大脑干位 (locus coeruleus,LC) 是用于嗅觉处理的诺亚上腺素 (NA) 的关键来源,在阿尔茨海默病早期受到影响.
研究的目的:
- 研究阿尔茨海默病早期嗅觉缺陷背后的机制.
- 探索诺亚上腺素 (NA) 途径和微质活性在前性AD中的作用.
主要方法:
- 利用阿尔茨海默病小鼠模型 (AppNL-G-F) 研究嗅觉功能和LC-OB神经电路.
- 在嗅球 (OB) 中检查了LC轴突的微细胞化.
- 评估了前期阿兹海默症患者的TSPO-PET信号,并分析了早期阿兹海默症患者的死后嗅觉球泡组织.
主要成果:
- 在AD小鼠模型中,在粉样斑块形成之前,已经证明了对嗅球 (OB) 早期的诺亚上腺素 (NA) 输入的损失.
- 确定了OB微细胞的细胞化LC轴突作为NA轴突损失和随后的低血的机制.
- 在前进性AD患者的OB中观察到高TSPO-PET信号,并在早期AD患者的OB中确认LC轴突退化.
结论:
- 嗅觉球 (OB) 中的偏 (locus coeruleus,LC) 早期损伤和随后的北上腺 (noradrenergic,NA) 轴突损失导致阿尔茨海默病的低血.
- NA轴突的微质细胞分裂是AD早期的关键病理机制.
- 嗅觉测试和嗅觉通路的神经成像为早期AD诊断和干预提供了潜力.
相关概念视频
Olfactory Receptors: Location and Structure
9.6K
The process of olfaction, also known as the sense of smell, is a sophisticated chemical response system. The specialized sensory neurons that facilitate this process, known as olfactory receptor neurons, are situated in an upper segment of the nasal cavity, known as the olfactory epithelium. Olfactory sensory neurons are bipolar, with their dendrites extending from the epithelium's apex into the mucus that lines the nasal cavity. Airborne molecules, when inhaled, traverse the olfactory...
9.6K
Alzheimer's Disease: Overview
668
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
668
Olfaction
45.2K
The sense of smell is achieved through the activities of the olfactory system. It starts when an airborne odorant enters the nasal cavity and reaches olfactory epithelium (OE). The OE is protected by a thin layer of mucus, which also serves the purpose of dissolving more complex compounds into simpler chemical odorants. The size of the OE and the density of sensory neurons varies among species; in humans, the OE is only about 9-10 cm2.
The olfactory receptors are embedded in the cilia of the...
The olfactory receptors are embedded in the cilia of the...
45.2K
Alzheimer's Disease: Treatment
261
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
261
Neural Regulation
40.0K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
40.0K

